^
Association details:
| Biomarker: | EGFR positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ameile (aumolertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR
Excerpt:
...Positive EGFR driver mutation (rare mutation other than 19 exon deletion or L858R) detected by tumor tissue or blood samples....
Trial ID:
Source:
Title:
Mechanism of resistance to second-line Aumolertinib and exploring combined treatment after resistance
Excerpt:
...Patients with locally advanced (stage IIIB) or metastatic (stage IV) NON-small cell lung cancer with positive EGFR-resistant mutations who are unable to undergo curative surgery or radiotherapy and whose T790M mutation is confirmed; 2. ...
Trial ID:
Less C2 evidence
Source:
Title:
Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR+ NSCLC Patients: The Updated Results
Published date:
08/08/2023
Excerpt:
A total of 86 patients (43% were male) were included. Overall, ORR and DCR were 74.4% and 97.7%, respectively. 46 patients were ≥ 65 yr (range, 65-86) and 40 patients were < 65 yr (range, 32-64). ORR was 69.6% and 80.0% for patients ≥ 65 and < 65 yr, respectively (p=0.27), and DCR was 97.8% and 97.5%, respectively (p=0.93)...The first-line therapy with aumolertinib showed excellent and encouraging results in this real-world study. The efficacy and safety profile of aumolertinib as first-line therapy in elderly EGFR+ NSCLC patients were similar to that seen in the younger subgroup.
